In March 2022, FDA approved Opdualag, i.e., a combination of immune checkpoint inhibitors, Nivolumab & Relatlimab-rmbw, for patients aged 12 years or older with unresectable or metastatic melanoma. Both drugs block proteins on immune cells, which, in turn, releases the immune response against cancer cells.
โถ๏ธ ๐๐ฉ๐๐๐ค ๐ญ๐จ ๐ญ๐ก๐ ๐๐ง๐๐ฅ๐ฒ๐ฌ๐ญ ๐๐จ๐ซ ๐ฆ๐จ๐ซ๐ ๐๐๐ญ๐๐ข๐ฅ๐ฌ: - https://lnkd.in/dQxvbzmw
#malignant_melanoma_market #tumour #cancer #allergies #melanoma #biopsy #drugs #healthcare #marketresearch #marknteladvisors
Like
Comment
Share
1 (877) 773-1002